

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

00 AUG 10 PM 2:09

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Tongour Simpson Group LLC-formerly "Tongour Group"			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 227 Massachusetts Avenue, NE Suite 1 City Washington State/Zip (or Country) DC 20002			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name John "Brad" Holsclaw		Telephone 202-544-7600	E-mail (optional) holsclaw@cais.net
		5. Senate ID # 5147875	
7. Client Name <input type="checkbox"/> Self Aventis Pharmaceuticals, Inc. formerly "Hoechst Marion Roussel, Inc."		6. House ID # 34927003	

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$60,000.00</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

John B. Holsclaw

Date 8/8/2000

Printed Name and Title John "Brad" Holsclaw - Partner

Page 1 of 4

Registrant Name: Tongour Simpson Group LLC-formerly "Tongour Group"

Client Name: Aventis Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

Potential patent legislation which would affect the introduction of drugs into the market.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Holsclaw, John "Brad"		No
Tongour, Michael		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Aventis Pharmaceuticals, Inc. is wholly owned by Aventis Pharma AG headquartered in Frankfurt, Germany. This is a pharmaceutical company which is owned by Aventis S.A. with global headquarters in Strasbourg, France. Both companies business interests would be affected by the issue in line 16.

Signature John B. Holsclaw Date 8/8/2000

Printed Name and Title John "Brad" Holsclaw - Partner Page 2 of 4

Registrant Name: Tongour Simpson Group LLC-formerly "Tongour Group"

Client Name: Aventis Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues

H.R.664, H.R.371, S.2536, H.R.4461, specifically provisions relating to the costs of prescription drugs and their importation and reimportation.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Holsclaw, John "Brad"		No
Tongour, Michael		No

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Aventis Pharmaceuticals, Inc. is wholly owned by Aventis Pharma AG headquartered in Frankfurt, Germany. This is a pharmaceutical company which is owned by Aventis S.A. with global headquarters in Strasbourg, France. Both companies business interests would be affected by the issue in line 16.

Signature



Date 8/8/2008

Printed Name and Title John "Brad" Holsclaw - Partner

Page 3 of 4

Registrant Name: Tongour Simpson Group LLC-formerly "Tongour Group"

Client Name: Aventis Pharmaceuticals, Inc.

Information Update Page - Complete ONLY where registration information has changed.

20 Client new address

801 Pennsylvania Avenue, NW, Suite 725, , Washington, DC, 20004

21 Client new principal place of business (if different from line 20)

22 Parsippany State/Zip (or Country) NJ, 07054

23 New general description of client's business or activities

LOBBYIST UPDATE

23 Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24 General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25 Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26 Name of each previously reported organization that is no longer affiliated with the registrant or client


FOREIGN ENTITIES

27 Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Ownership % in client
Aventis Pharma AG	D-65926 Frankfurt, Germany	Germany	\$0.00	100.00%

28 Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client, or affiliated organization

Signature



Date 8/8/2000

Printed Name and Title John "Brad" Holsclaw - Partner

Page 4 of 4